Bluejay Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing ...
The directors of the Irish arm of pharma giant Roche have stated that there is a need to reduce the lengthy timelines to ...
Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.
Irish Examiner on MSN1d
Profits at Irish arm of Roche pharma climb by 17%Latest news on Ireland's companies and busines organisations and their impact locally, nationally and globally.
Accord BioPharma Inc., the U.S. specialty division of Intas Pharmaceuticals Ltd., has reached an exclusive commercialization and license agreement with Bio-Thera Solutions for BAT2506, a biosimilar ...
Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...
In this video, Annick Desjardins, MD, professor of neurosurgery, professor of neurology and member of the Duke Cancer Institute, explains how clinicians may treat patients with gliomas of different ...
Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...
Nuvectis is also advancing NXP900 for YES1/SRC-expressing solid tumors, with promising early data showing no dose-limiting ...
Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...
Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback